{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:30:15Z","timestamp":1791469815519,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.joca.2014.10.005","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T20:45:39Z","timestamp":1418762739000},"page":"S18-S21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":174,"special_numbering":"S1","title":["Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies"],"prefix":"10.1016","volume":"23","author":[{"given":"M.C.","family":"Hochberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joca.2014.10.005_bib1","first-page":"94","article-title":"Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain","volume":"12","author":"Cattaneo","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.joca.2014.10.005_bib2","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa0901510","article-title":"Tanezumab for the treatment of pain from osteoarthritis of the knee","volume":"383","author":"Lane","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.joca.2014.10.005_bib3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.joca.2011.01.009","article-title":"Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain","volume":"19","author":"Schnitzer","year":"2011","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2014.10.005_bib4","article-title":"Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis","volume":"185","author":"Evans","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.joca.2014.10.005_bib5","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.pain.2011.05.003","article-title":"Efficacy and safety of tanezumab in the treatment of chronic low back pain","volume":"152","author":"Katz","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.joca.2014.10.005_bib6","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.joca.2011.09.006","article-title":"Tanezumab investigators: preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study","volume":"19","author":"Nagashima","year":"2011","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2014.10.005_bib7","first-page":"790","article-title":"Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial","volume":"13","author":"Brown","year":"2012","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.joca.2014.10.005_bib8","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.urology.2012.07.035","article-title":"Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis\/chronic pelvic pain syndrome","volume":"80","author":"Nickel","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.joca.2014.10.005_bib9","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/art.37950","article-title":"Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial","author":"Brown","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2014.10.005_bib10","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.pain.2013.03.006","article-title":"Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain","volume":"154","author":"Kivitz","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.joca.2014.10.005_bib11","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.pain.2013.04.035","article-title":"A\u00a0phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee","volume":"154","author":"Spierings","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.joca.2014.10.005_bib12","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/j.pain.2013.05.051","article-title":"Efficacy, safety and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patient with moderate to severe osteoarthritis pain","volume":"154","author":"Sanga","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.joca.2014.10.005_bib13","article-title":"Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicenter phase III randomized clinical trial","author":"Balanescu","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2014.10.005_bib14","first-page":"E45","article-title":"Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis","volume":"17","author":"Leite","year":"2014","journal-title":"Pain Physician"},{"key":"10.1016\/j.joca.2014.10.005_bib15","article-title":"Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain","author":"Schnitzer","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2014.10.005_bib16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40265-014-0208-6","article-title":"Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?","volume":"74","author":"Bannwarth","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.joca.2014.10.005_bib17","unstructured":"Tanezumab Arthritis Advisory Committee Briefing Document, Pfizer February 8, 2012."},{"issue":"10,Suppl l","key":"10.1016\/j.joca.2014.10.005_bib18","first-page":"S113","article-title":"Adjudication of reported serious adverse joint events in the tanezumab clinical development program","volume":"64","author":"Hochberg","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2014.10.005_bib19","unstructured":"JNJ-42160443 (fulranumab) Advisory Committee Briefing Document, Janssen Research & Development, L.L.C., January 31, 2012."},{"issue":"Suppl 1","key":"10.1016\/j.joca.2014.10.005_bib20","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1016\/j.joca.2013.02.605","article-title":"Adjudication process for joint events of interest in fulranumnab clinical trial program","volume":"21","author":"Moskowitz","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2014.10.005_bib21","first-page":"1435","article-title":"Rapidly destructive osteoarthritis of the hip","volume":"78","author":"Lequesne","year":"1970","journal-title":"La Presse Medicale"},{"issue":"2","key":"10.1016\/j.joca.2014.10.005_bib22","first-page":"187","article-title":"Rapidly progressive osteoarthritis of the hip","volume":"13","author":"Della Torre","year":"1987","journal-title":"Ital J Orthop Traumatol"},{"key":"10.1016\/j.joca.2014.10.005_bib23","first-page":"62","article-title":"Rapidly progressing destructive diseases of the hip","volume":"36","author":"Lequesne","year":"1993","journal-title":"Ann Radiol (Paris)"},{"key":"10.1016\/j.joca.2014.10.005_bib24","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0883-5403(98)80007-7","article-title":"Rapidly progressive osteoarthrosis of the hip","volume":"13","author":"Irwin","year":"1998","journal-title":"J\u00a0Arthoplasty"},{"issue":"5","key":"10.1016\/j.joca.2014.10.005_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s002560100348","article-title":"Subchondral insufficiency fracture of the femoral head: histopathologic correlation with MRI","volume":"30","author":"Yamamoto","year":"2001","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.joca.2014.10.005_bib26","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2214\/ajr.179.3.1790657","article-title":"Rapidly destructive osteoarthritis of the hip: MR imaging findings","volume":"179","author":"Boutry","year":"2002","journal-title":"Am J Roentgenol"},{"issue":"12","key":"10.1016\/j.joca.2014.10.005_bib27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/ard.2007.085019","article-title":"Rapid destruction of the hip joint in osteoarthritis","volume":"67","author":"Yamamoto","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2014.10.005_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00256-009-0834-3","article-title":"Bilateral rapidly destructive arthrosis of the hip joint resulting from subchondral fracture with superimposed secondary osteonecrosis","volume":"39","author":"Yamamoto","year":"2010","journal-title":"Skeletal Radiol"},{"issue":"2","key":"10.1016\/j.joca.2014.10.005_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ocl.2008.10.010","article-title":"Osteonecrosis of the knee: a review of three disorders","volume":"40","author":"Zywiel","year":"2009","journal-title":"Orthop Clin North Am"},{"key":"10.1016\/j.joca.2014.10.005_bib30","doi-asserted-by":"crossref","first-page":"482","DOI":"10.5435\/00124635-201108000-00004","article-title":"Osteonecrosis of the knee and related conditions","volume":"19","author":"Mont","year":"2011","journal-title":"J\u00a0Am Acad Orthop Surg"},{"key":"10.1016\/j.joca.2014.10.005_bib31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3928\/01477447-20130122-04","article-title":"Differentiation, diagnosis, and treatment of osteoarthritis, osteonecrosis, and rapidly progressive osteoarthritis","volume":"36","author":"Pivec","year":"2013","journal-title":"Orthopedics"},{"issue":"1","key":"10.1016\/j.joca.2014.10.005_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CND.0b013e3181c6f55b","article-title":"The Charcot joint: a modern neurologic perspective","volume":"13","author":"Chisholm","year":"2011","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.joca.2014.10.005_bib33","first-page":"1941","article-title":"Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis","volume":"22","author":"Huskisson","year":"1995","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2014.10.005_bib34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1177\/0091270003256061","article-title":"The mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: a concise review","volume":"43","author":"Harder","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.joca.2014.10.005_bib35","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0889-857X(03)00061-9","article-title":"Microfractures and microcracks in subchondral bone: are they relevant to osteoarthrosis?","volume":"29","author":"Burr","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.joca.2014.10.005_bib36","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00167-012-2095-2","article-title":"The effect of nonsteroidal anti-inflammatory drugs on tissue healing","volume":"21","author":"Chen","year":"2013","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"10.1016\/j.joca.2014.10.005_bib37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1742-7843.2007.00149.x","article-title":"Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process","volume":"102","author":"Vuolteenaho","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.joca.2014.10.005_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/14740338.3.2.131","article-title":"COX inhibitors and their effects on bone healing","volume":"3","author":"Gerstenfeld","year":"2004","journal-title":"Expert Opin Drug Saf"}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458414012989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458414012989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:35:22Z","timestamp":1761017722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458414012989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":38,"alternative-id":["S1063458414012989"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2014.10.005","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2014.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}